Research programme: anti-hypertensive therapy - Pfizer
Latest Information Update: 06 Aug 2009
At a glance
- Originator Pfizer
- Class Heterocyclic compounds
- Mechanism of Action Renin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Hypertension
Most Recent Events
- 05 Aug 2009 Preclinical development is ongoing in USA
- 10 Apr 2006 Preclinical trials in Hypertension in USA (PO)